Unissant

 

Unissant Adds New GSA Health IT Special Item Number (SIN)

10:07 23 August in Pressroom
0 Comments

Reston, VA – August 22, 2016 – Unissant recognizes that innovation drives transformation. Nowhere is this more evident than in healthcare. Through advancements in emerging technology, Unissant is committed to helping improve the health, wellness, and patient care of our nation.

Early last week, Unissant Inc. announced that a modification was received from the U.S. General Services Administration (GSA), in which a new Health IT Special Item Number (SIN) 132-56, will be added to the company’s existing IT Schedule 70 (GS-35F-0298T).

GSA developed the Health IT SIN to support federal agencies in meeting their highly specialized requirements when it comes to finding IT expertise. Unissant has been providing Health IT solutions to commercial, state and local and federal government customers since 2006.

“As the healthcare market continues to grow, Unissant looks forward to expanding our role in healthcare IT services. This Health IT SIN will offer Unissant the ability to expand and refine our healthcare technology services,” stated Chief Marketing Officer Jango Unwalla.

The new SIN allows Unissant to provide solutions to across the federal health IT field, including areas such as health data analytics, innovative health IT solutions, and health informatics.

About Unissant
Unissant provides advanced data analytics that empower our clients to meet their business goals. We have deep expertise in health IT, national security, financial services, and energy. Unissant delivers innovative, cost-effective solutions to large government agencies and Fortune 100 companies. Founded in 2006, Unissant is a SDB, CMMI Level 3 company with offices in Reston, Virginia and San Antonio, Texas. In August 2015, Unissant was named by Inc. magazine as one of the nation’s fastest-growing private companies (the Inc. 5000 list). www.unissant.com


Media Contact: Jango Unwalla
[email protected]
703.889.8500 x 114

Unissant PR

[email protected]
No Comments

Sorry, the comment form is closed at this time.